CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Payments for Restructuring
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Payments for Restructuring of $32.20 million for the 6-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2026-08-05
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. payments for restructuring for the quarter ending 2026-06-27 was $14.90M, a 17.95% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. payments for restructuring for the quarter ending 2026-03-28 was $17.30M, a 20.84% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. payments for restructuring for the quarter ending 2025-12-27 was $12.00M, a 35.68% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. payments for restructuring for the quarter ending 2025-09-27 was $13.99M, a 35.90% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. payments for restructuring for fiscal 2025 was $58.47M, a 34.90% increase from fiscal 2024.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. payments for restructuring for fiscal 2024 was $43.34M, a 349.43% increase from fiscal 2023.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. payments for restructuring for fiscal 2023 was $9.64M, a 32.88% increase from fiscal 2022.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. payments for restructuring for fiscal 2022 was $7.26M, a 29.50% increase from fiscal 2021.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 3 month as first filed | Payments for Restructuring 6 month | Payments for Restructuring 9 month | Payments for Restructuring 9 month as first filed | Payments for Restructuring 12 month | Payments for Restructuring 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-27 | $14.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $32.20M 10-Q · filed 2026-08-05 | $44.20M derived: sum of 3 quarters · filed 2026-08-05 | $58.19M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2026-03-28 | $17.30M 10-Q · filed 2026-05-07 | $29.30M derived: sum of 2 quarters · filed 2026-05-07 | $43.29M derived: sum of 3 quarters · filed 2026-05-07 | $61.45M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-12-27 | $12.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $25.99M derived: sum of 2 quarters · filed 2026-02-18 | $44.15M derived: sum of 3 quarters · filed 2026-08-05 | $58.47M 10-K · filed 2026-02-18 | |||
| 2025-09-27 | $13.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $32.15M derived: sum of 2 quarters · filed 2026-08-05 | $46.47M 10-Q · filed 2025-11-05 | $65.12M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-06-28 | $18.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $32.48M 10-Q · filed 2026-08-05 | $51.13M derived: sum of 3 quarters · filed 2026-08-05 | $61.43M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-03-29 | $14.32M 10-Q · filed 2026-05-07 | $32.98M derived: sum of 2 quarters · filed 2026-05-07 | $43.27M derived: sum of 3 quarters · filed 2026-05-07 | $51.92M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-28 | $18.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $28.95M derived: sum of 2 quarters · filed 2026-02-18 | $37.60M derived: sum of 3 quarters · filed 2026-02-18 | $43.34M 10-K · filed 2026-02-18 | |||
| 2024-09-28 | $10.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $18.95M derived: sum of 2 quarters · filed 2025-11-05 | $24.68M 10-Q · filed 2025-11-05 | $30.44M derived: sum of 4 quarters · filed 2026-02-18 | |||
| 2024-06-29 | $8.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $14.39M 10-Q · filed 2025-08-06 | $20.14M derived: sum of 3 quarters · filed 2026-02-18 | $22.92M derived: sum of 4 quarters · filed 2026-02-18 | |||
| 2024-03-30 | $5.73M 10-Q · filed 2025-05-07 | $3.23M 10-Q · filed 2024-05-09 | $11.49M derived: sum of 2 quarters · filed 2026-02-18 | $14.26M derived: sum of 3 quarters · filed 2026-02-18 | $15.05M derived: sum of 4 quarters · filed 2026-02-18 | ||
| 2023-12-30 | $5.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $8.53M derived: sum of 2 quarters · filed 2026-02-18 | $9.31M derived: sum of 3 quarters · filed 2026-02-18 | $9.64M 10-K · filed 2026-02-18 | $7.80M 10-K · filed 2024-02-14 | ||
| 2023-09-30 | $2.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $3.56M derived: sum of 2 quarters · filed 2024-11-06 | $3.89M 10-Q · filed 2024-11-06 | ||||
| 2023-07-01 | $783.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $1.11M 10-Q · filed 2024-08-07 | |||||
| 2023-04-01 | $331.00K 10-Q · filed 2024-05-09 | ||||||
| 2022-12-31 | $7.26M 10-K · filed 2025-02-19 | $6.97M 10-K · filed 2024-02-14 | |||||
| 2021-12-25 | $5.60M 10-K · filed 2024-02-14 | ||||||
| 2015-06-27 | $1.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-30 | $2.77M 10-Q · filed 2015-07-30 | $5.81M derived: sum of 3 quarters · filed 2015-07-30 | $6.92M derived: sum of 4 quarters · filed 2015-07-30 | |||
| 2015-03-28 | $1.62M 10-Q · filed 2015-04-30 | $4.66M derived: sum of 2 quarters · filed 2015-04-30 | $5.78M derived: sum of 3 quarters · filed 2015-04-30 | $8.39M derived: sum of 4 quarters · filed 2015-04-30 | |||
| 2014-12-27 | $3.04M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-17 | $4.16M derived: sum of 2 quarters · filed 2015-02-17 | $6.77M derived: sum of 3 quarters · filed 2015-02-17 | $7.91M 10-K · filed 2015-02-17 | |||
| 2014-09-27 | $1.12M 10-Q · filed 2014-10-30 | $3.73M derived: sum of 2 quarters · filed 2014-10-30 | $4.87M 10-Q · filed 2014-10-30 | $6.86M derived: sum of 4 quarters · filed 2015-02-17 | |||
| 2014-06-28 | $2.61M 10-Q · filed 2014-08-07 | $3.75M 10-Q · filed 2014-08-07 | $5.74M derived: sum of 3 quarters · filed 2015-02-17 | $6.52M derived: sum of 4 quarters · filed 2015-02-17 | |||
| 2014-03-29 | $1.14M 10-Q · filed 2014-04-30 | $3.13M derived: sum of 2 quarters · filed 2015-02-17 | $3.91M derived: sum of 3 quarters · filed 2015-02-17 | $4.71M derived: sum of 4 quarters · filed 2015-02-17 | |||
| 2013-12-28 | $1.99M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-17 | $2.78M derived: sum of 2 quarters · filed 2015-02-17 | $3.58M derived: sum of 3 quarters · filed 2015-02-17 | $4.08M 10-K · filed 2015-02-17 | |||
| 2013-09-28 | $783.00K 10-Q · filed 2014-10-30 | $1.59M derived: sum of 2 quarters · filed 2014-10-30 | $2.08M 10-Q · filed 2014-10-30 | -$2.08M 10-Q · filed 2013-10-30 | $5.81M derived: sum of 4 quarters · filed 2015-02-17 | ||
| 2013-06-29 | $803.00K 10-Q · filed 2014-08-07 | $1.30M 10-Q · filed 2014-08-07 | $5.03M derived: sum of 3 quarters · filed 2015-02-17 | ||||
| 2013-03-30 | $498.00K 10-Q · filed 2014-04-30 | $4.23M derived: sum of 2 quarters · filed 2015-02-17 | |||||
| 2012-12-29 | $3.73M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-17 | $2.31M 10-K · filed 2015-02-17 | |||||
| 2012-09-29 | -$1.42M 10-Q · filed 2013-10-30 | ||||||
| 2011-12-31 | $12.75M 10-K · filed 2014-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |